- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Combination Product · Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 3,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Placebo, Fluticasone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 45
- States / cities
- Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
- Conditions
- Asthma, COPD
- Interventions
- beclamethasone dipropionate, albuterol, Prednisone
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Asthma
- Interventions
- Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
- Conditions
- Bronchopulmonary Dysplasia, Very Low Birth Weight
- Interventions
- Varied albuterol dose response
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 14 Days and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Bromide, Fluticasone Propionate/Salmeterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 35
- States / cities
- Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- QVA149, NVA237, tiotropium, Salbutamol/albuterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
- Interventions
- Nebulized arformoterol, Salmeterol
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Asthma
- Interventions
- Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 100
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
- Conditions
- Asthma
- Interventions
- RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 33
- States / cities
- Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Interventions
- Albuterol
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 25
- States / cities
- Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more
- Conditions
- Asthma Placebo Effects
- Interventions
- albuterol, placebo inhaler, placebo acupuncture
- Drug · Procedure
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
- Conditions
- Asthma
- Interventions
- Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 9 Years
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
- Conditions
- Asthma
- Interventions
- OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
- Drug
- Lead sponsor
- Oriel Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 47
- States / cities
- Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
- Conditions
- Asthma
- Interventions
- Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI
- Combination Product · Drug · Other
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 1,001 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 73
- States / cities
- Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more
- Conditions
- Asthma
- Interventions
- BDA MDI, AS MDI
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 113
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 91 more
- Conditions
- Asthma
- Interventions
- FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
- Conditions
- Asthma
- Interventions
- MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
- Drug
- Lead sponsor
- Mylan Pharma UK Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 116
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
- Conditions
- Asthma
- Interventions
- Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 56
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more